Company profile for AlloVir

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At AlloVir (formerly ViraCyte) it’s our mission to develop and deliver transformative cell therapies for patients suffering from life-threatening virus-associated diseases. We are the leader in the clinical development of novel cell therapies designed to restore natural T-cell immunity against devastating virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients. AlloVir has...
At AlloVir (formerly ViraCyte) it’s our mission to develop and deliver transformative cell therapies for patients suffering from life-threatening virus-associated diseases. We are the leader in the clinical development of novel cell therapies designed to restore natural T-cell immunity against devastating virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients. AlloVir has built an innovative technology platform developed by researchers at Baylor College of Medicine’s Center for Cell and Gene Therapy.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Kirby Grove 2925 Richmond Ave, Suite 1200 Houston, TX 77098
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2025/03/18/3044996/0/en/Kalaris-Announces-Closing-of-Merger-with-AlloVir.html

GLOBENEWSWIRE
18 Mar 2025

https://www.globenewswire.com/news-release/2025/03/12/3041732/0/en/Kalaris-and-AlloVir-Announce-Stockholder-Approval-of-Merger.html

GLOBENEWSWIRE
12 Mar 2025

https://www.fiercebiotech.com/biotech/struggling-allovir-finds-new-identity-merging-eye-disease-biotech

FIERCE BIOTECH
11 Nov 2024

https://www.globenewswire.com/news-release/2024/11/08/2977479/0/en/AlloVir-and-Kalaris-Therapeutics-Announce-Agreement-for-Transformational-Merger-to-Create-Company-Focused-on-Diseases-of-the-Retina.html

GLOBENEWSWIRE
08 Nov 2024

https://endpts.com/allovir-lays-off-95-of-workers-after-canceling-phiii-antiviral-cell-therapy-studies/

Anna Brown ENDPTS
05 Jan 2024
Reeling from triple phase 3 failure, AlloVir cuts 95% of staff
Reeling from triple phase 3 failure, AlloVir cuts 95% of staff

05 Jan 2024

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/reeling-triple-phase-3-failure-allovir-cuts-95-workforce

Annalee Armstrong FIERCE BIOTECH
05 Jan 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty